[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582140":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":45,"collaborators":26,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":26,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":26,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Medical University of Silesia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LP299v group","EXPERIMENTAL","Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.",[13],"Dietary Supplement: Prevention of C. difficile infections using LP299v strain LP299v",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.",[19],"Dietary Supplement: Prevention of C. difficile infections using LP299v strain Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Prevention of C. difficile infections using LP299v strain Placebo","Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.\n\nOne capsule of placebo orally per a day during the entire period of antibiotic therapy.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Prevention of C. difficile infections using LP299v strain LP299v","Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.\n\nOne capsule of LP299v orally per a day during the entire period of antibiotic therapy.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Sylwia Dudzicz-Gojowy, PhD, MD","CONTACT","+48322591432","sdudzicz@sum.edu.pl",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":41,"countryCode":44,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Department of Nephrology, Transplantation and Intenal Medicine Medical University of Silesia","RECRUITING","Poland","Silesian Voivodeship","40-027","PL",{"type":46,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100582140","prevention-of-clostridium-difficile-infections-using-lactobacillus-plantarum-299v-strain-in-nephrology-and-transplantation-department-100582140",false,"NCT06859437","Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department","Inclusion Criteria:\n\n* over 18 years old\n* organ transplantation or receiving immunosuppressive drugs for any other reasons\n* antibiotics therapy\n\nExclusion Criteria:\n\n* no consent to participate in the study","ALL","18 Years",{"count":56,"type":57},300,"ESTIMATED","INTERVENTIONAL",[60],"NA","The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward.\n\nAdutt patients from risk group (receiving immunosuppressive drugs and treated with antibiotics) were enrolled into study.\n\nPatients who meet the above criteria for inclusion in the study will be assigned to one of two groups. Patients in group I (study) will receive a probiotic containing the Lactobacillus plantarum 299v strain of bacteria as part of the prophylaxis of Clostridioides difficile infection. The daily dose is 1 capsule containing approximately 10x109 colony-forming units of live bacteria taken orally with a meal. Patients in group II (control) will receive a placebo. The duration of probiotic or placebo use will be 3 months. Assignment to groups I and II will be random. The number of patients in each group will be 150.\n\nParticipants will be divided into two groups. First group will receive one capsule of Lactobacillus plantarum 299v (LP299v) orally per a day. Second group will receive placebo. The observation period will last 3 months. The evaluation will consist of an interview, physical examination and laboratory tests.",[63],"Clostridioides Difficile Infection","2025-02-27",{"date":66,"type":67},"2025-03-05","ACTUAL",{"date":69,"type":67},"2024-10-01",{"date":71,"type":57},"2027-10-31",{"name":5,"class":6},1]